A study of M254 (Hyper-sialylated IVIg)

Next Previous
Trial Profile

A study of M254 (Hyper-sialylated IVIg)

Planning
Phase of Trial: Phase I

Latest Information Update: 21 Feb 2018

At a glance

  • Drugs M-254 (Primary)
  • Indications Autoimmune disorders; Inflammation
  • Focus Adverse reactions

    • Most Recent Events

    • 21 Feb 2018 According to a Momenta Pharmaceuticals media release, company is planning to initiate this trial in first half of 2018.
    • 08 May 2017 New trial record
    • 02 May 2017 According to a Momenta Pharmaceuticals media release, company is planning to initiate clinical trial in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top